Profile data is unavailable for this security.
About the company
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.
- Revenue in INR (TTM)58.90bn
- Net income in INR6.92bn
- Incorporated1978
- Employees4.22k
- LocationGland Pharma LtdSurvey No.143-148,150&151Near Gandimaisamma 'X' RoadsD.P Pally, Dundigal Gandimaisamma MandaHYDERABAD 500043IndiaIND
- Phone+91 4 030510999
- Fax+91 4 030510800
- Websitehttps://glandpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuland Laboratories Ltd. | 15.28bn | 2.80bn | 190.57bn | 1.65k | 68.14 | 13.73 | 55.46 | 12.47 | 217.98 | 217.98 | 1,191.20 | 1,081.52 | 0.847 | 2.14 | 4.85 | 9,273,565.00 | 15.50 | 9.25 | 20.03 | 12.71 | 52.14 | 47.81 | 18.30 | 11.99 | 1.40 | 31.56 | 0.0728 | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Eris Lifesciences Ltd | 24.98bn | 3.48bn | 200.59bn | 3.08k | 57.62 | 7.23 | 32.20 | 8.03 | 25.57 | 25.57 | 183.35 | 203.74 | 0.4585 | 2.90 | 5.96 | 8,110,753.00 | 6.73 | 13.42 | 8.39 | 16.80 | 77.03 | 79.98 | 14.69 | 24.96 | 0.8599 | 3.41 | 0.4626 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Wockhardt Ltd | 29.49bn | -2.88bn | 210.41bn | 2.39k | -- | 5.85 | -- | 7.13 | -19.85 | -19.85 | 201.29 | 221.32 | 0.393 | 1.87 | 4.19 | 12,318,300.00 | -3.93 | -4.56 | -6.33 | -8.29 | 59.10 | 55.26 | -10.00 | -12.70 | 0.5677 | 0.247 | 0.3869 | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Alembic Pharmaceuticals Ltd | 63.57bn | 6.47bn | 214.88bn | 14.86k | 33.25 | 4.40 | 23.24 | 3.38 | 32.88 | 32.88 | 323.14 | 248.68 | 0.929 | 0.9366 | 5.43 | 4,278,678.00 | 9.45 | 10.72 | 13.32 | 14.25 | 73.84 | 65.98 | 10.17 | 12.47 | 0.8057 | 12.62 | 0.1791 | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Concord Biotech Ltd | 10.86bn | 3.28bn | 215.70bn | 1.38k | 55.66 | 13.56 | 56.51 | 19.87 | 37.04 | 37.04 | 114.79 | 152.02 | 0.655 | 1.11 | 3.55 | 7,884,886.00 | 19.78 | -- | 21.82 | -- | 76.00 | -- | 30.20 | -- | 4.83 | 194.73 | 0.0022 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
| Pfizer Ltd | 22.38bn | 6.18bn | 240.58bn | 1.72k | 38.94 | 6.41 | 35.44 | 10.75 | 135.06 | 135.06 | 489.19 | 819.90 | 0.5288 | 1.83 | 11.16 | 13,004,360.00 | 14.60 | 14.22 | 17.05 | 17.71 | 65.00 | 61.37 | 27.61 | 24.05 | 4.30 | 46.21 | 0.0267 | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Natco Pharma Ltd. | 45.61bn | 19.45bn | 244.48bn | 4.02k | 12.57 | 3.42 | 11.46 | 5.36 | 108.58 | 108.58 | 254.65 | 399.19 | 0.6291 | 0.8928 | 3.57 | 11,356,080.00 | 26.82 | 12.33 | 30.85 | 14.25 | 85.47 | 73.05 | 42.63 | 25.16 | 4.19 | 108.70 | 0.0283 | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -4.71 | 14.87 |
| Emcure Pharmaceuticals Ltd | 72.56bn | 5.67bn | 248.11bn | 11.15k | 43.20 | 6.02 | 25.83 | 3.42 | 30.37 | 30.37 | 389.63 | 217.79 | 0.978 | 1.80 | 3.96 | 6,510,068.00 | 8.02 | 7.14 | 13.55 | 13.93 | 61.11 | 59.29 | 8.20 | 7.81 | 0.9549 | 5.25 | 0.2165 | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 37.11bn | 6.11bn | 272.50bn | 5.31k | 45.63 | 8.48 | 35.46 | 7.34 | 38.45 | 38.45 | 233.33 | 206.82 | 0.9481 | 2.59 | 4.85 | 6,987,882.00 | 15.61 | 15.77 | 18.62 | 18.89 | 66.26 | 61.18 | 16.47 | 16.06 | 2.20 | 27.53 | 0.0303 | 33.08 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
| Laurus Labs Ltd | 50.53bn | 1.31bn | 286.86bn | 6.01k | 218.69 | 6.94 | 52.61 | 5.68 | 2.43 | 2.43 | 93.70 | 76.70 | 0.602 | 1.18 | 3.06 | 8,412,186.00 | 1.55 | 10.13 | 2.52 | 16.47 | 53.44 | 47.63 | 2.58 | 12.83 | 0.5818 | 1.81 | 0.4023 | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| Gland Pharma Ltd | 58.90bn | 6.92bn | 292.26bn | 4.22k | 42.26 | 3.33 | 27.18 | 4.96 | 41.98 | 41.98 | 357.57 | 533.41 | 0.5567 | 1.28 | 4.11 | 13,967,630.00 | 6.54 | 13.23 | 7.65 | 14.56 | 60.30 | 55.58 | 11.74 | 22.92 | 3.14 | 33.11 | 0.0358 | 7.26 | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
| Suven Pharmaceuticals Ltd | 9.61bn | 2.43bn | 329.38bn | 1.05k | 135.68 | 16.65 | 108.56 | 34.27 | 9.54 | 9.54 | 37.73 | 77.71 | 0.4156 | 1.52 | 5.99 | 9,136,501.00 | 10.50 | 23.17 | 11.50 | 26.20 | 61.42 | 58.85 | 25.27 | 33.21 | 4.00 | 29.50 | 0.0191 | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
| Piramal Pharma Ltd | 87.04bn | 453.30m | 330.35bn | 6.72k | 734.62 | 4.18 | 41.06 | 3.80 | 0.3407 | 0.3407 | 66.36 | 59.91 | 0.5799 | 1.40 | 4.88 | 12,954,040.00 | 0.302 | -- | 0.428 | -- | 63.69 | -- | 0.5208 | -- | 0.5603 | 7.49 | 0.3771 | -- | 15.39 | -- | 109.56 | -- | -- | -- |
| Ajanta Pharma Ltd | 44.91bn | 8.75bn | 374.32bn | 7.84k | 43.09 | 10.18 | 36.99 | 8.34 | 69.55 | 69.55 | 356.94 | 294.36 | 0.9738 | 1.33 | 4.16 | 5,725,128.00 | 18.97 | 16.61 | 23.29 | 20.47 | 75.77 | 73.22 | 19.48 | 19.31 | 2.13 | 49.88 | 0.0088 | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
| GlaxoSmithKline Pharmaceuticals Limited | 35.60bn | 6.75bn | 396.69bn | 3.21k | 59.13 | 23.72 | 53.35 | 11.14 | 39.60 | 39.60 | 209.31 | 98.74 | 1.01 | 2.59 | 14.85 | 11,088,370.00 | 19.24 | 11.01 | 36.09 | 17.88 | 61.70 | 55.77 | 18.96 | 12.25 | 1.38 | 554.80 | 0.0088 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
| IPCA Laboratories Ltd | 85.33bn | 6.61bn | 407.74bn | 17.34k | 61.65 | 6.09 | 38.22 | 4.78 | 26.07 | 26.07 | 336.37 | 264.10 | 0.7483 | 1.12 | 4.78 | 4,922,642.00 | 5.88 | 10.33 | 9.00 | 13.52 | 67.36 | 59.16 | 7.85 | 12.25 | 1.32 | 25.33 | 0.129 | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
Data as of Nov 26 2024. Currency figures normalised to Gland Pharma Ltd's reporting currency: Indian Rupee INR
32.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Oct 2024 | 12.74m | 7.73% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Oct 2024 | 10.29m | 6.24% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Oct 2024 | 9.17m | 5.57% |
| ICICI Prudential Asset Management Co. Ltd.as of 15 Nov 2024 | 6.96m | 4.23% |
| SBI Funds Management Ltd.as of 15 Nov 2024 | 4.92m | 2.99% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Oct 2024 | 2.15m | 1.30% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Oct 2024 | 2.06m | 1.25% |
| Goldman Sachs Asset Management LPas of 08 Nov 2024 | 1.97m | 1.20% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 1.42m | 0.86% |
| DSP Asset Managers Pvt. Ltd.as of 31 Oct 2024 | 1.07m | 0.65% |
More ▼
Data from 30 Jun 2024 - 21 Nov 2024Source: FactSet Research Systems Inc.
